Ge Long Hui·2026-02-26 08:55Core Viewpoint - The company, CanSino Biologics (06185.HK), reported a significant improvement in its financial performance for the fiscal year 2025, achieving a total revenue of approximately RMB 1,067.91 million, representing a year-on-year growth of 26.18% and turning a profit for the first time in years [1][2] Financial Performance - The total revenue for the year reached approximately RMB 1,067.91 million, marking a year-on-year increase of 26.18% [1][2] - The net profit attributable to the owners of the parent company was approximately RMB 27.87 million, indicating a turnaround from previous losses [1] - The net loss attributable to the owners of the parent company, after excluding non-recurring gains and losses, was approximately RMB 92.50 million, showing a narrowing of losses compared to the previous year [1][2] Strategic Initiatives - The company continued to focus on innovation and commercialization, with the successful growth of its first quadrivalent meningococcal vaccine, Manhaixin [1] - Cost reduction and efficiency improvement measures were effectively implemented, leading to better expense management and an increase in gross margin [1] - The company benefited from government grants and international research funding, which contributed to non-recurring income during the reporting period [1][2] Operational Efficiency - The company achieved a turnaround in operating profit, total profit, and net profit attributable to the owners of the parent company, all showing positive year-on-year growth [2] - Basic earnings per share and the weighted average return on equity turned positive, reflecting improved operational efficiency [2] - The narrowing of net loss attributable to the owners of the parent company, after excluding non-recurring items, was primarily due to revenue growth and effective resource allocation [2]